Less Intense Surveillance Acceptable for Some Prostate Cancer Cases

Share this content:
Some individuals with prostate cancer may receive unnecessary active surveillance.
Some individuals with prostate cancer may receive unnecessary active surveillance.

(HealthDay News) -- Certain patients on active surveillance for prostate cancer may be eligible for less intensive surveillance, according to a study published in the January issue of The Journal of Urology.

Evan Kovac, M.D., from the Cleveland Clinic, and colleagues identified 300 men on active surveillance from a prospective database; the men had undergone initial surveillance prostate biopsy, with or without confirmatory biopsy, within one year of diagnosis. Eighty-seven percent were classified as having National Comprehensive Cancer Network very-low-risk or low-risk disease at diagnosis. The presence of 50 percent or more positive cores and/or surveillance prostate biopsy Gleason score upgrading was used to define disease reclassification on active surveillance.

The researchers found that 16 and 6 percent of patients had type I and II reclassification, respectively, at the time of initial surveillance prostate biopsy. The rates of type I and type II reclassification at initial surveillance prostate biopsy were reduced for those who underwent confirmatory biopsy (9 versus 23 percent [P = 0.001] and 3 versus 9 percent [P = 0.01], respectively). The two-year rates of subsequent type I and II reclassification were 17 and 3 percent, respectively, for the 251 patients without disease reclassification at initial surveillance prostate biopsy.

"Patients on active surveillance with stable disease at the time of initial surveillance prostate biopsy may be appropriate candidates for less intensive surveillance prostate biopsy schedules," the authors write.

One author disclosed financial ties to Cook and Healthtronics.

Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs